華陽集團(002906.SZ):中山中科及中科白雲減持期屆滿 擬再減持不超6%股份
格隆匯5月10日丨華陽集團(002906.SZ)公佈,截至本公吿披露日,公司持股5%以上股東中山中科股權投資有限公司(以下簡稱“中山中科”)、珠海橫琴中科白雲股權投資基金合夥企業(有限合夥)(以下簡稱“中科白雲”)前次股份減持計劃時間已屆滿,本次減持期限內,中山中科及中科白雲累計減持公司股份1671.25萬股,佔公司總股本的3.53%。
中山中科及中科白雲擬繼續減持公司股份,計劃通過集中競價或大宗交易方式合計減持公司股份不超過2838.6萬股(即不超過公司總股本的6%)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.